Lactokinin
Lactokinin is an Endothelin-1 (HY-P0202) release inhibitor and ACE inhibitor, with an ACE IC50 value of 29 μM. Lactokinin binds to bovine β-lactoglobulin variant A to form a non-covalent complex, which delays its hydrolysis by chymotrypsin, as well as by pepsin/chymotrypsin, in vitro. Lactokinin can be used in research related to hypertension.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 132160-04-4
- 分子式: C37H64N12O8S
- 分子量:837.04
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
Lactokinin is bound to purified bovine β-lactoglobulin variant A via non-covalent interactions, and the bound peptide is protected from oxidation and ion adduction during ionization compared to free lactokinin[1].
Lactokinin (0.1-1 mM) inhibits basal and thrombin-stimulated endothelin-1 release from cultured porcine aortic endothelial cells, with 1 mM reducing basal release by 29% and 0.1 mM and 1 mM reducing thrombin-stimulated release by 32% and 43%, respectively[2].
Lactokinin inhibits porcine kidney angiotensin-converting enzyme activity with an IC50 of 29 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 132160-04-4
-
分子量 837.04
-
分子式 C37H64N12O8S
-
SMILES
C[C@H](N)C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CCSC)C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)CC2=CN=CN2)=O)=O)=O)=O
-
配列
Ala-Leu-Pro-Met-His-Ile-Arg
-
シーケンスの短縮
ALPMHIR
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
[2]. Maes W, et al. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regulatory peptides. 2004 Apr 15;118(1-2):105-9. [Content Brief]
[3]. Pina AS, et al. Studies on the molecular recognition between bioactive peptides and angiotensin-converting enzyme. Journal of molecular recognition : JMR. 2009;22(2):162-8. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)